{"cluster": 57, "subcluster": 15, "abstract_summ": "We compared clinical features and SARS-CoV-2 RNA shedding between patients with LPV/r treatment and those without.We compared clinical characteristics and SARS-CoV-2 RNA shedding between patients initiated with LPV/r treatment and those without.Patients who initiated LPV/r treatment within 10 days from symptom onset, but not initiated from day 11 onwards, had significantly shorter viral shedding duration compared with those without LPV/r treatment (median 19 days versus 28.5 days, Log-rank p<0.001).Older age (odd ratio [OR] 1.03, 95% confidence interval [CI] 1.00\u20131.05, p=0.03) and the lack of LPV/r treatment (OR 2.42, 95% CI 1.10\u20135.36, p=0.029) were independent risk factors of prolonged SARS-CoV-2 RNA shedding.However, studies regarding the risk factors associated with prolonged SARS-CoV-2 shedding and the impact of Lopinavir/Ritonavir (LPV/r) treatment on viral shedding remain scarce.", "title_summ": "Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infectionArbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infectionLopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID\u201019: a retrospective study in two designated hospitals in Anhui, ChinaA Trial of Lopinavir\u2013Ritonavir in Adults Hospitalized with Severe Covid-19Antiviral Activity and Safety of Darunavir/Cobicistat for Treatment of COVID-19", "title_abstract_phrases": "Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infectionBackground: The duration of viral shedding is central to guide decisions around isolation precautions and antiviral treatment.We compared clinical features and SARS-CoV-2 RNA shedding between patients with LPV/r treatment and those without.We compared clinical characteristics and SARS-CoV-2 RNA shedding between patients initiated with LPV/r treatment and those without.In conclusion, our data indicate that arbidol monotherapy may be superior to lopinavir/ritonavir in treating COVID-19.Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infectionBACKGROUND: The duration of viral shedding is central to guide the decisions of isolation precautions and antiviral treatment.Lopinavir/ritonavir and interferon combination therapy may help shorten the duration of viral shedding in patients with COVID\u201019: a retrospective study in two designated hospitals in Anhui, ChinaBACKGROUND: Prolonged viral shedding may pose a threat to the control of coronavirus disease 2019 (COVID\u201019), and data on the duration of SARS\u2010CoV\u20102 shedding are still limited, with the associated factors being unknown."}